Both semaglutide and tirzepatide should help people with Type 2 diabetes lower their HbA1c, a measure of blood glucose over ...

Certain companies seem particularly relentless. Their ads don’t explicitly name the drugs they prescribe, but they don’t need to. Suggestive phrases like “doctor-supported weight loss” and “clinically ...

Q. I have something like varicose veins in my nose that cause frequent nosebleeds. My nose is often dry regardless of weather conditions.

After deciding that tirzepatide was no longer in short supply, the FDA removed it from the official list ... FDA changed its status via a post on its website on 2nd October based on statements ...

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...

Dr. Nabil Adra The Big Ten CRC, which uses the Big Ten Conference’s official logo, specializes in something known as investigator-initiated trials. That means a researcher, like a medical school ...

Eli Lilly's medicines, such as Mounjaro and Zepbound, are racking up incredible sales, and they are still on an upward path. Further, other recent launches should soon contribute to the drugmaker ...